The characteristics of patients with multiple myeloma surviving over 10 years
ObjectiveTo explore the characteristics of patients with multiple myeloma (MM) who have achieved long-term survival of over 10 years in the context where novel agents and autologous stem cell transplantation (ASCT) serve as the primary therapeutic modalities.MethodsA retrospective analysis was condu...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1490630/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846161483359059968 |
|---|---|
| author | Beihui Huang Hongning Zhang Junru Liu Jingli Gu Meilan Chen Lifen Kuang Xiaozhe Li Juan Li |
| author_facet | Beihui Huang Hongning Zhang Junru Liu Jingli Gu Meilan Chen Lifen Kuang Xiaozhe Li Juan Li |
| author_sort | Beihui Huang |
| collection | DOAJ |
| description | ObjectiveTo explore the characteristics of patients with multiple myeloma (MM) who have achieved long-term survival of over 10 years in the context where novel agents and autologous stem cell transplantation (ASCT) serve as the primary therapeutic modalities.MethodsA retrospective analysis was conducted on 168 MM patients diagnosed and treated in our institution from January 2004 to January 2014. 44 patients with a survival period exceeding 10 years were categorized into the long-term survival group, while 124 patients with a survival period of less than 10 years were categorized into the non-long-term survival group.ResultsBeing younger than 57 years old (OR 3.634, 95%CI 1.302-10.143), having a neutrophil count of at least 3.66 * 109/L (OR 3.122, 95% CI 1.093-8.918), absence of high-risk genetic abnormalities (OR 7.146, 95%CI 1.066-47.904), and receiving frontline ASCT (OR 4.225, 95%CI 1.000-17.841) were positively associated with a survival period exceeding 10 years in patients with MM. Achieving sustained minimal residual disease (MRD) negativity for at least 24 months is associated with long-term survival regardless of the presence of high-risk cytogenetic abnormalities.ConclusionBeing younger, having a neutrophil count above 3.66 * 109/L, the absence of high-risk cytogenetic abnormalities, and receiving frontline ASCT are independent protective factors for transplant-eligible MM patients to survive more than 10 years. Achieving maintained MRD negativity status for over 24 months might be associated with long-term survival. |
| format | Article |
| id | doaj-art-9b5b4af2d49c460191d64aa143490d7b |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9b5b4af2d49c460191d64aa143490d7b2024-11-21T06:23:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14906301490630The characteristics of patients with multiple myeloma surviving over 10 yearsBeihui HuangHongning ZhangJunru LiuJingli GuMeilan ChenLifen KuangXiaozhe LiJuan LiObjectiveTo explore the characteristics of patients with multiple myeloma (MM) who have achieved long-term survival of over 10 years in the context where novel agents and autologous stem cell transplantation (ASCT) serve as the primary therapeutic modalities.MethodsA retrospective analysis was conducted on 168 MM patients diagnosed and treated in our institution from January 2004 to January 2014. 44 patients with a survival period exceeding 10 years were categorized into the long-term survival group, while 124 patients with a survival period of less than 10 years were categorized into the non-long-term survival group.ResultsBeing younger than 57 years old (OR 3.634, 95%CI 1.302-10.143), having a neutrophil count of at least 3.66 * 109/L (OR 3.122, 95% CI 1.093-8.918), absence of high-risk genetic abnormalities (OR 7.146, 95%CI 1.066-47.904), and receiving frontline ASCT (OR 4.225, 95%CI 1.000-17.841) were positively associated with a survival period exceeding 10 years in patients with MM. Achieving sustained minimal residual disease (MRD) negativity for at least 24 months is associated with long-term survival regardless of the presence of high-risk cytogenetic abnormalities.ConclusionBeing younger, having a neutrophil count above 3.66 * 109/L, the absence of high-risk cytogenetic abnormalities, and receiving frontline ASCT are independent protective factors for transplant-eligible MM patients to survive more than 10 years. Achieving maintained MRD negativity status for over 24 months might be associated with long-term survival.https://www.frontiersin.org/articles/10.3389/fonc.2024.1490630/fullmultiple myelomalong-term survivalprognostic factorssurvival analysisminimal residual disease |
| spellingShingle | Beihui Huang Hongning Zhang Junru Liu Jingli Gu Meilan Chen Lifen Kuang Xiaozhe Li Juan Li The characteristics of patients with multiple myeloma surviving over 10 years Frontiers in Oncology multiple myeloma long-term survival prognostic factors survival analysis minimal residual disease |
| title | The characteristics of patients with multiple myeloma surviving over 10 years |
| title_full | The characteristics of patients with multiple myeloma surviving over 10 years |
| title_fullStr | The characteristics of patients with multiple myeloma surviving over 10 years |
| title_full_unstemmed | The characteristics of patients with multiple myeloma surviving over 10 years |
| title_short | The characteristics of patients with multiple myeloma surviving over 10 years |
| title_sort | characteristics of patients with multiple myeloma surviving over 10 years |
| topic | multiple myeloma long-term survival prognostic factors survival analysis minimal residual disease |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1490630/full |
| work_keys_str_mv | AT beihuihuang thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT hongningzhang thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT junruliu thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT jingligu thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT meilanchen thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT lifenkuang thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT xiaozheli thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT juanli thecharacteristicsofpatientswithmultiplemyelomasurvivingover10years AT beihuihuang characteristicsofpatientswithmultiplemyelomasurvivingover10years AT hongningzhang characteristicsofpatientswithmultiplemyelomasurvivingover10years AT junruliu characteristicsofpatientswithmultiplemyelomasurvivingover10years AT jingligu characteristicsofpatientswithmultiplemyelomasurvivingover10years AT meilanchen characteristicsofpatientswithmultiplemyelomasurvivingover10years AT lifenkuang characteristicsofpatientswithmultiplemyelomasurvivingover10years AT xiaozheli characteristicsofpatientswithmultiplemyelomasurvivingover10years AT juanli characteristicsofpatientswithmultiplemyelomasurvivingover10years |